There were 2,011 press releases posted in the last 24 hours and 440,820 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image